Amicus Therapeutics (NASDAQ:FOLD) Hits New 52-Week Low – Should You Sell?

Amicus Therapeutics, Inc. (NASDAQ:FOLD) hit a new 52-week low on Thursday . The company traded as low as $5.81 and last traded at $5.87, with a volume of 120687 shares. The stock had previously closed at $5.88.

Analyst Upgrades and Downgrades

FOLD has been the subject of several analyst reports. UBS Group lifted their price target on shares of Amicus Therapeutics from $21.00 to $22.00 and gave the stock a “buy” rating in a research report on Friday, May 2nd. StockNews.com cut shares of Amicus Therapeutics from a “buy” rating to a “hold” rating in a research report on Monday, May 5th. Wells Fargo & Company lowered their price target on shares of Amicus Therapeutics from $18.00 to $17.00 and set an “overweight” rating for the company in a research report on Thursday, February 20th. Needham & Company LLC reiterated a “hold” rating on shares of Amicus Therapeutics in a research report on Thursday, February 20th. Finally, The Goldman Sachs Group lowered their price target on shares of Amicus Therapeutics from $12.00 to $9.00 and set a “neutral” rating for the company in a research report on Friday, May 2nd. Four investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $16.22.

Amicus Therapeutics Stock Performance

The stock has a market cap of $1.98 billion, a price-to-earnings ratio of -35.72, a PEG ratio of 1.51 and a beta of 0.64. The stock’s fifty day moving average is $7.37 and its 200-day moving average is $8.92. The company has a quick ratio of 2.42, a current ratio of 3.39 and a debt-to-equity ratio of 2.01.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of FOLD. Wellington Management Group LLP grew its holdings in Amicus Therapeutics by 18.8% during the fourth quarter. Wellington Management Group LLP now owns 28,461,994 shares of the biopharmaceutical company’s stock valued at $268,112,000 after purchasing an additional 4,497,950 shares during the period. Nuveen LLC acquired a new position in shares of Amicus Therapeutics in the first quarter valued at approximately $28,741,000. Vestal Point Capital LP acquired a new position in shares of Amicus Therapeutics in the fourth quarter valued at approximately $31,557,000. Norges Bank acquired a new position in shares of Amicus Therapeutics in the fourth quarter valued at approximately $29,033,000. Finally, Millennium Management LLC boosted its holdings in shares of Amicus Therapeutics by 635.1% in the first quarter. Millennium Management LLC now owns 3,359,389 shares of the biopharmaceutical company’s stock valued at $27,413,000 after buying an additional 2,902,375 shares during the period.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.